- Home
- CGAU vs INVA Comparison
CGAU vs INVA Comparison
Compare CGAU & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGAU | INVA |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 1.6B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | CGAU | INVA |
|---|---|---|
| Price | $14.36 | $20.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $14.17 | ★ $36.80 |
| AVG Volume (30 Days) | ★ 1.0M | 1.0M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | ★ 236.39 | 53.96 |
| EPS | ★ 1.60 | 1.52 |
| Revenue | ★ $1,285,392,000.00 | $388,521,000.00 |
| Revenue This Year | $14.70 | $13.23 |
| Revenue Next Year | $12.63 | $8.62 |
| P/E Ratio | ★ $8.66 | $13.11 |
| Revenue Growth | 2.66 | ★ 10.14 |
| 52 Week Low | $5.41 | $16.52 |
| 52 Week High | $14.73 | $22.76 |
Technical Indicators
Market Signals| Indicator | CGAU | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 70.30 | 41.77 |
| Support Level | $13.63 | $19.72 |
| Resistance Level | $14.46 | $21.00 |
| Average True Range (ATR) | 0.49 | 0.52 |
| MACD | 0.03 | -0.19 |
| Stochastic Oscillator | 85.36 | 19.81 |
Price Performance
Historical ComparisonAbout CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.